Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.

KURA

Kura Oncology (KURA)

Kura Oncology Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:KURA
FechaHoraFuenteTítuloSímboloCompañía
20/11/202416:21Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KURAKura Oncology Inc
20/11/202416:00PR Newswire (US)Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute LeukemiasNASDAQ:KURAKura Oncology Inc
19/11/202415:05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KURAKura Oncology Inc
18/11/202415:03Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:KURAKura Oncology Inc
07/11/202415:15Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:KURAKura Oncology Inc
07/11/202415:05GlobeNewswire Inc.Kura Oncology Reports Third Quarter 2024 Financial ResultsNASDAQ:KURAKura Oncology Inc
05/11/202408:09GlobeNewswire Inc.Kura Oncology to Present Updated Data from KOMET-007 Combination Trial of Ziftomenib at ASH Annual MeetingNASDAQ:KURAKura Oncology Inc
31/10/202406:30GlobeNewswire Inc.Kura Oncology to Report Third Quarter 2024 Financial ResultsNASDAQ:KURAKura Oncology Inc
24/10/202406:30GlobeNewswire Inc.Kura Oncology Reports Preclinical Data Supporting Opportunity for Ziftomenib in Treatment of Gastrointestinal Stromal Tumors (GIST)NASDAQ:KURAKura Oncology Inc
23/10/202406:30GlobeNewswire Inc.Kura Oncology to Present New Data Supporting Combination of KO-2806 with KRAS G12C and Pan-RAS InhibitorsNASDAQ:KURAKura Oncology Inc
30/09/202417:30GlobeNewswire Inc.Kura Oncology Announces Publication of Ziftomenib Phase 1 Results in The Lancet OncologyNASDAQ:KURAKura Oncology Inc
17/09/202415:10Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:KURAKura Oncology Inc
17/09/202406:30GlobeNewswire Inc.Kura Oncology Appoints Michael Vasconcelles, M.D., to Board of DirectorsNASDAQ:KURAKura Oncology Inc
10/09/202406:30GlobeNewswire Inc.Kura Oncology to Participate in Cantor Global Healthcare ConferenceNASDAQ:KURAKura Oncology Inc
08/08/202415:05GlobeNewswire Inc.Kura Oncology Reports Second Quarter 2024 Financial ResultsNASDAQ:KURAKura Oncology Inc
08/08/202406:30GlobeNewswire Inc.Kura Oncology Announces FDA Clearance of IND Application for Menin Inhibitor Ziftomenib in Advanced Gastrointestinal Stromal Tumors (GIST)NASDAQ:KURAKura Oncology Inc
01/08/202406:30GlobeNewswire Inc.Kura Oncology to Report Second Quarter 2024 Financial ResultsNASDAQ:KURAKura Oncology Inc
05/07/202406:30GlobeNewswire Inc.Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:KURAKura Oncology Inc
24/06/202406:30GlobeNewswire Inc.Kura Oncology Reports Preclinical Data Supporting Potential for Menin Inhibitor in DiabetesNASDAQ:KURAKura Oncology Inc
07/06/202415:30Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:KURAKura Oncology Inc
29/05/202406:30GlobeNewswire Inc.Kura Oncology to Participate in Jefferies Global Healthcare ConferenceNASDAQ:KURAKura Oncology Inc
14/05/202406:30GlobeNewswire Inc.Kura Oncology Completes Enrollment in Registration-Directed Trial of Ziftomenib in NPM1-Mutant AMLNASDAQ:KURAKura Oncology Inc
08/05/202406:30GlobeNewswire Inc.Kura Oncology to Participate in Bank of America Securities Healthcare ConferenceNASDAQ:KURAKura Oncology Inc
02/05/202415:05GlobeNewswire Inc.Kura Oncology Reports First Quarter 2024 Financial ResultsNASDAQ:KURAKura Oncology Inc
25/04/202406:30GlobeNewswire Inc.Kura Oncology to Report First Quarter 2024 Financial ResultsNASDAQ:KURAKura Oncology Inc
22/04/202406:30GlobeNewswire Inc.Kura Oncology Receives Breakthrough Therapy Designation for Ziftomenib in NPM1-Mutant AMLNASDAQ:KURAKura Oncology Inc
10/04/202406:30GlobeNewswire Inc.Kura Oncology to Participate in Stifel Targeted Oncology ForumNASDAQ:KURAKura Oncology Inc
06/03/202406:30GlobeNewswire Inc.Kura Oncology Reports First Patient Dosed in Trial of KO-2806 Plus Cabozantinib in Renal Cell CarcinomaNASDAQ:KURAKura Oncology Inc
27/02/202415:01GlobeNewswire Inc.Kura Oncology Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:KURAKura Oncology Inc
26/02/202406:30GlobeNewswire Inc.Kura Oncology Doses First Patient in KOMET-008 Trial of Ziftomenib in Combination with Standards of Care, Including FLT3 Inhibitor, in Acute Myeloid LeukemiaNASDAQ:KURAKura Oncology Inc
 Showing the most relevant articles for your search:NASDAQ:KURA

Su Consulta Reciente

Delayed Upgrade Clock